Benjamin Sack

Venture Firm

We partner with founders for their journey ahead, investing with flexibility and scale to build companies that last.

Sands Capital is an active, long-term investor in leading innovative growth businesses, globally. Our approach combines analytical rigor and creative thinking to identify high-quality growth businesses that are creating the future. Through an integrated investment platform spanning venture capital, growth equity and public equity, we provide growth capital solutions to institutions and fund sponsors in more than 40 countries. An independent, staff-owned firm founded in 1992 and headquartered in the Washington, D.C. area with offices in London and Singapore, Sands Capital managed more than $53 billion in client assets as of June 30, 2024.   Careers: https://www.sandscapital.com/careers Disclosures and definitions: https://www.sandscapital.com/disclosures

Upwork is the world’s work marketplace that connects businesses with independent talent from across the globe. We serve everyone from one-person startups to large, Fortune 100 enterprises with a powerful, trust-driven platform that enables companies and talent to work together in new ways that unlock their potential. Our talent community on Upwork encompasses more than 10,000 skills in categories including website & app development, creative & design, customer support, finance & accounting, consulting, and operations.

Venture Firm

We are building an exciting new breed bioscience company through the combination of early-stage novel science and long-term shareholder capital. Cambridge Science Corporation (CSC) launched in 2018 with the mission of improving patient lives through the acceleration of translational research and creating long-term value for our shareholders. We are pursuing internal drug development programs and we launch, finance, and manage biotech companies commercializing novel technologies developed in the top labs at the world’s premier research institutions. Our primary goals are to help patients by focusing on opportunities that address large unmet medical needs and to create long-term value for our shareholders. Our research and development capital allocation process prioritizes three characteristics of successful biotech companies in order: people, science, and intellectual property.